肾功能与阿尔茨海默病及相关痴呆血液和脑脊液生物标志物的系统综述与荟萃分析
该系统综述与荟萃分析纳入93项研究、62503名成人,评估肾功能与阿尔茨海默病及相关痴呆血液和脑脊液生物标志物的关联。结果显示,较低的肾功能(主要为eGFR)与血液NfL、GFAP和Aβ40浓度升高相关,而与脑脊液生物标志物的关联不一致且多无统计学意义。
要点
- 肾功能下降与血液NfL、GFAP和Aβ40升高独立相关。
- 肾功能与脑脊液生物标志物的关联不一致且多无统计学意义。
- 肾功能受损者血液生物标志物升高可能反映肾脏清除减少。
核心结论
- 低肾功能与阿尔茨海默病及相关痴呆的血液生物标志物(NfL、GFAP、Aβ40)升高相关。
- 肾功能与脑脊液生物标志物的关联不一致且多无统计学意义。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、EMBASE、Cochrane Library和Web of Science至2025年5月2日。
- 纳入93项研究,共62503名参与者(年龄20-96岁,54%女性),来自21个国家。
主要发现
- 未调整相关系数荟萃分析中,肾功能(主要为eGFR)与血液NfL、GFAP、Aβ40、β-淀粉样蛋白1-40、β-淀粉样蛋白1-42和磷酸化tau(p-tau181)浓度呈负相关。
- 调整回归系数荟萃分析中,eGFR每降低1 ml/min per 1.73 m²,血液NfL升高0.19 pg/ml(95%CI 0.12至0.25),GFAP升高0.11 pg/ml(95%CI 0.04至0.18),Aβ40升高0.29 pg/ml(95%CI 0.01至0.56)。
- 脑脊液生物标志物 findings 异质性更大且总体无统计学意义。
临床怎么用
- 解读阿尔茨海默病及相关痴呆血液生物标志物时需考虑肾功能,避免将肾功能下降所致的标志物升高误判为神经退行性病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Lower kidney function is associated with higher concentrations of blood biomarkers for Alzheimer's disease and related dementia. Associations between kidney function and cerebrospinal fluid biomarkers for Alzheimer's disease and related dementia were heterogeneous and NS. Elevated blood biomarkers for Alzheimer's disease and related dementia in people with impaired kidney function may reflect reduced kidney clearance. BACKGROUND: Studies have shown that low kidney function may link to elevated Alzheimer's disease and related dementia fluid biomarkers, but the results are not consistent. This systematic review and meta-analysis aimed to investigate whether kidney function was associated with Alzheimer's disease and related dementia biomarkers (amyloid- β , tau, neurofilament light [NfL] protein, and glial fibrillary acidic protein [GFAP]) in blood and cerebrospinal fluid (CSF). METHODS: Human studies were identified through MEDLINE, EMBASE, Cochrane Library, and Web of Science (until May 2, 2025). Studies that reported the association between kidney function and Alzheimer's disease and related dementia biomarkers in blood or CSF among adults were included. Two authors independently screened and extracted data following preferred reporting items for systematic reviews and meta-analyses 2020 guidelines. Descriptive statistics and random-effects meta-analysis were used to analyze pooled effects. RESULTS: Of the 3024 studies screened, 93 met the inclusion criteria, encompassing 62,503 participants (mean age, 20-96 years; 54% female) from 21 countries. Ninety-one studies reported blood biomarkers, while ten reported CSF biomarkers. In meta-analysis of unadjusted correlation coefficients, kidney function (primarily eGFR) was inversely associated with concentrations of blood NfL, GFAP, Aβ40, β-amyloid 1-40 (A β 40), β-amyloid 1-42, and phosphorylated tau (p-tau181). In meta-analysis of adjusted regression coefficients, eGFR remained inversely associated with blood biomarker levels. Specifically, every 1 ml/min per 1.73 m 2 lower eGFR was associated with 0.19 pg/ml higher NfL (95% confidence interval [CI], 0.12 to 0.25), 0.11 pg/ml higher GFAP (95% CI, 0.04 to 0.18), and 0.29 pg/ml higher A β 40 (95% CI, 0.01 to 0.56). CSF biomarker findings were more heterogeneous and generally null. CONCLUSIONS: Low kidney function was associated with elevated blood biomarkers of Alzheimer's disease and related dementia (NfL, GFAP, and A β 40), whereas associations with CSF biomarkers were inconsistent and generally null.
引用
- Lin Y, Zhao Z, Zhu N, et al. Kidney Function and Blood and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Related Dementias: Systematic Review and Meta-Analysis. J Am Soc Nephrol. 2026. PMID: 41587095. doi:10.1681/ASN.0000001007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。